Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1 - PubMed (original) (raw)
Review
Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1
S P Henry et al. Toxicol Pathol. 1999 Jan-Feb.
Abstract
ISIS 2302 is a phosphorothioate oligodeoxynucleotide with a sequence complementary to the mRNA of human intercellular adhesion molecule 1 (ICAM-1). Hybridization of ISIS 2302 to the mRNA inhibits expression of the ICAM-1 protein in response to inflammatory stimuli. A murine active antisense oligonucleotide, ISIS 3082, has been used for in vivo pharmacology studies and has anti-inflammatory activity in models of organ transplant rejection, ulcerative colitis, and collagen-induced arthritis at doses ranging from 0.03 to 5 mg/kg. The safety assessment for ISIS 2302 includes general toxicity studies up to 6 mo in duration in mice and monkeys, genetic toxicity studies, and reproductive/fertility studies. ISIS 3082 was examined in parallel with ISIS 2302 in mouse toxicity and reproductive studies. The toxicities observed following systemic administration of ISIS 2302 and ISIS 3082 were similar and consistent with those observed for other compounds in this chemical class and, therefore, are independent of the suppression of ICAM-1 expression. Toxicokinetic evaluation demonstrated that toxicities occurred in organs containing the highest concentrations of ISIS 2302. Evidence of immune stimulation. including dose-dependent splenomegaly, lymphoid hyperplasia, and multiorgan mixed mononuclear cell infiltrates, was the most common finding in rodent studies. Monkeys were much less sensitive than mice to immune stimulation. Kidney contained the highest concentrations of ISIS 2302. Morphologic changes observed in kidney included atrophic and regenerative changes in proximal tubular epithelium; however, there was no evidence of functional abnormalities. Additional histologic changes noted in proximal tubular epithelium included basophilic granules, which were reflective of oligonucleotide distribution and uptake in these cells. Liver also contained high concentrations of oligonucleotide, which were associated with Kupffer cell hypertrophy in mice. Changes in serum transaminases, cholesterol, and triglycerides were reflective of hepatic alterations. In monkeys, high concentrations of oligonucleotide caused a transient increase in clotting times and activation of the alternative complement pathway. All toxicities associated with ISIS 2302 were reversible and occurred at doses well above those required for pharmacologic activity or currently used in clinical trials. In addition, there has been no evidence of genetic toxicity associated with ISIS 2302, and no changes in reproductive performance, fertility, or fetal development have been noted in animals treated with ISIS 2302 or ISIS 3082.
Similar articles
- Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.
Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ. Henry SP, et al. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):473-81. doi: 10.1089/oli.1.1997.7.473. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9361906 - Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.
Henry SP, Denny KH, Templin MV, Yu RZ, Levin AA. Henry SP, et al. Birth Defects Res B Dev Reprod Toxicol. 2004 Dec;71(6):359-67. doi: 10.1002/bdrb.20023. Birth Defects Res B Dev Reprod Toxicol. 2004. PMID: 15617021 - Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.
Henry SP, Bolte H, Auletta C, Kornbrust DJ. Henry SP, et al. Toxicology. 1997 Jun 27;120(2):145-55. doi: 10.1016/s0300-483x(97)03661-5. Toxicology. 1997. PMID: 9184201 - Alicaforsen. Isis Pharmaceuticals.
Gewirtz AT, Sitaraman S. Gewirtz AT, et al. Curr Opin Investig Drugs. 2001 Oct;2(10):1401-6. Curr Opin Investig Drugs. 2001. PMID: 11890355 Review. - Synthetic oligonucleotides: the development of antisense therapeutics.
Monteith DK, Levin AA. Monteith DK, et al. Toxicol Pathol. 1999 Jan-Feb;27(1):8-13. doi: 10.1177/019262339902700103. Toxicol Pathol. 1999. PMID: 10367666 Review.
Cited by
- Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties.
Miroshnichenko SK, Patutina OA, Burakova EA, Chelobanov BP, Fokina AA, Vlassov VV, Altman S, Zenkova MA, Stetsenko DA. Miroshnichenko SK, et al. Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1229-1234. doi: 10.1073/pnas.1813376116. Epub 2019 Jan 8. Proc Natl Acad Sci U S A. 2019. PMID: 30622178 Free PMC article. - Aptamer Therapeutics in Cancer: Current and Future.
Morita Y, Leslie M, Kameyama H, Volk DE, Tanaka T. Morita Y, et al. Cancers (Basel). 2018 Mar 19;10(3):80. doi: 10.3390/cancers10030080. Cancers (Basel). 2018. PMID: 29562664 Free PMC article. Review. - Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides.
Wada F, Yamamoto T, Kobayashi T, Tachibana K, Ito KR, Hamasaki M, Kayaba Y, Terada C, Yamayoshi A, Obika S, Harada-Shiba M. Wada F, et al. Mol Ther Nucleic Acids. 2021 Oct 19;26:957-969. doi: 10.1016/j.omtn.2021.10.008. eCollection 2021 Dec 3. Mol Ther Nucleic Acids. 2021. PMID: 34760338 Free PMC article. - Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate.
Coughlin JE, Pandey RK, Padmanabhan S, O'Loughlin KG, Marquis J, Green CE, Mirsalis JC, Iyer RP. Coughlin JE, et al. Drug Metab Dispos. 2012 May;40(5):970-81. doi: 10.1124/dmd.111.044446. Epub 2012 Feb 10. Drug Metab Dispos. 2012. PMID: 22328581 Free PMC article. - Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.
Rabinovich-Guilatt L, Elgart A, Erisson L, Willsie SK, Tessler S, Barnett-Griness O, Pande A, Spiegelstein O. Rabinovich-Guilatt L, et al. Br J Clin Pharmacol. 2015 Sep;80(3):436-45. doi: 10.1111/bcp.12633. Epub 2015 Jun 22. Br J Clin Pharmacol. 2015. PMID: 25782535 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous